Multiple Myeloma

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Betsy O'Donnell, MD, discusses the utility of up-front triplet regimens in multiple myeloma.

Maria-Victoria Mateos, MD, PhD, discusses the data that led to the approval of the subcutaneous daratumumab formulation and the clinical implications of the regulatory decision.

The FDA has issued a Refusal to File letter to Bristol Myers Squibb and bluebird bio, Inc., regarding their Biologics License Application (BLA) for the BCMA-directed CAR T-cell therapy decabtagene vicleucel.

The FDA has requested additional details before accepting a biologics license application for idecabtagene vicleucel for the treatment of patients with multiple myeloma.

Maria-Victoria Mateos, MD, PhD, discusses the data that led to the approval of the subcutaneous daratumumab formulation and the clinical implications of the regulatory decision.

Marc J. Braunstein, MD, PhD, discusses updated results from the GRIFFIN trial in multiple myeloma.

Adding isatuximab to carfilzomib and dexamethasone improved progression-free survival in patients with relapsed multiple myeloma, meeting the primary end point of the phase 3 IKEMA trial.

Larry Anderson, MD, PhD, discusses recent advances made with novel therapies in multiple myeloma.

Nina Shah, MD and Sandy Wong, MD, discuss the predictive value of minimal residual disease and the need for treatment in a patient with smoldering multiple myeloma.

Marc J. Braunstein, MD, PhD, discusses quadruplet therapies in multiple myeloma.

Andrew Yee, MD, discusses the role of carfilzomib in relapsed/refractory multiple myeloma.

A European panel has recommended approval of a subcutaneous formulation of daratumumab for the treatment of patients with multiple myeloma.

A new drug application has been submitted in Japan seeking approval of a subcutaneous formulation of daratumumab.

Noopur Raje, MD, discusses future research with bispecific T-cell engagers in multiple myeloma.

Noopur Raje, MD, discusses the potential utility of belantamab mafodotin in multiple myeloma.

Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the role of venetoclax (Venclexta) in multiple myeloma.

Nina Shah, MD, highlights some of the recent advances that have been made with CAR T-cell therapy in multiple myeloma, as well as other exciting updates in the space.